SBIR/STTR Research Award
FISH Assay for Acute Myeloid Leukemia
Award amount
$226,508Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Gentris Corporation
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (Applicant's abstract): The goal of this research is to develop two
fluorescence in situ hybridization (FISH) assays for detecting the
t(8;21)(q22;q22) and inv(16)(p13q22) and related t(16;16)(p13;q22)
translocations found in two different subsets of acute myeloid leukemia (AML),
M2 and M4Eo, respectively. These cancers are traditionally treated by
chemotherapy; however, many patients relapse and become refractory to
treatment. Diagnosis and post treatment follow-up are currently performed by
karyotype, Southern blotting or PCR. These methods, however, have limitations
in specificity and/or sensitivity. A precise, reliable and simple method for
detecting cancer cells, especially in post-treatment specimens, is needed. FISH
is an improvement over current methods used for detecting translocations;
however, no clinically tested probes are available for detecting AML. This SBIR
proposal aims to develop novel, sensitive and specific FISH assays that will
unambiguously detect translocation carrying nuclei in diagnostic and follow up
patient samples.
PROPOSED COMMERCIAL APPLICATION:
The proposed research will provide highly specific and sensitive FISH assays for detecting
chromosomal translocations present in Acute Myeloid Leukemia (AML) for use in cancer
cytogenetic reference laboratories.
Technology keywords
Not reported